Compare Amgen, Inc. (AMGN) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Toronto-Dominion Bank — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Toronto-Dominion Bank trades at $120.25 (market cap $198.82B). The key difference: Amgen, Inc. and Toronto-Dominion Bank are close in size by market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | TD | |
|---|---|---|
Market Cap | $196.12B | $198.82B |
Sector | Health | Financials |
52-Week High | $388.16 | $122.25 |
52-Week Low | $271.18 | $72.55 |
Enterprise Value | $241.41B | — |
Dividend Yield | 2.77% | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
TD stock trades at $120.53, up 0.65% with a bullish technical signal and strong analyst consensus. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS expected at $1.71. Revenue grew to $61.28B in 2025 with a robust 23.38% net income margin, though cash flow from operations was negative. The stock trades at a P/E of 20.08 and P/B of 2.51, with a consensus price target of $153.00 representing 27% upside potential.
TD presents a compelling investment case with strong profitability metrics, consistent earnings beats, and positive analyst sentiment. Key risks include volatile operating cash flows, rising debt-to-asset ratios, and economic sensitivity. The current valuation appears reasonable relative to growth prospects, supported by institutional confidence and dividend stability. Upside potential exists if the company maintains its earnings momentum and executes on operational improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
